Fig. 5.
Fig. 5. Growth advantage in human CD34+ cells overexpressing HOXB4. / Human CD34+ cells overexpressing HOXB4 have a marked competitive growth advantage in NOD/SCID mice receiving transplants. (A) FACS analysis of human CD34+ cells expressing either GFP (top) or RFP (bottom) in marrow samples from mice that had received transplants with equal initial cell inoculums containing either HOXB4 (FMEV-HAHOXB4wPRE)– and RFP-transduced cells in a 1:2 ratio (HOXB4 versus RFP), or GFP- and RFP-transduced cells in a 1:1 ratio (GFP versus RFP). (B) In all mice receiving competitive transplants of HOXB4 versus RFP, HOXB4+(GFP+)CD34+ cells clearly dominated over RFP+CD34+ cells 8 weeks after transplantation. In contrast, in 3 of 6 mice of the GFP versus the RFP control group, RFP+CD34+cells predominated over GFP+CD34+ cells, whereas in the other 3 mice we observed the reverse.

Growth advantage in human CD34+ cells overexpressing HOXB4.

Human CD34+ cells overexpressing HOXB4 have a marked competitive growth advantage in NOD/SCID mice receiving transplants. (A) FACS analysis of human CD34+ cells expressing either GFP (top) or RFP (bottom) in marrow samples from mice that had received transplants with equal initial cell inoculums containing either HOXB4 (FMEV-HAHOXB4wPRE)– and RFP-transduced cells in a 1:2 ratio (HOXB4 versus RFP), or GFP- and RFP-transduced cells in a 1:1 ratio (GFP versus RFP). (B) In all mice receiving competitive transplants of HOXB4 versus RFP, HOXB4+(GFP+)CD34+ cells clearly dominated over RFP+CD34+ cells 8 weeks after transplantation. In contrast, in 3 of 6 mice of the GFP versus the RFP control group, RFP+CD34+cells predominated over GFP+CD34+ cells, whereas in the other 3 mice we observed the reverse.

Close Modal

or Create an Account

Close Modal
Close Modal